Dr. Pennell on the Cost Effectiveness of NGS in NSCLC
September 26th 2018Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the cost-effectiveness of next-generation sequencing for patients with metastatic non–small cell lung cancer.
Read More